Lexicon Pharmaceuticals to Host Conference Call and Webcast on January 17, 2019 to Discuss Outcome of FDA Advisory Committee ...
January 17 2019 - 6:20PM
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that
management will conduct a conference call and live webcast on
Thursday, January 17, 2019, at 7:00 p.m. EST (6:00 p.m. CST) to
discuss the outcome of the U.S. Food and Drug Administration (FDA)
Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC)
meeting in connection with the FDA’s review of Lexicon collaborator
Sanofi’s New Drug Application (NDA) for sotagliflozin, an
investigational oral treatment for adults with type 1 diabetes.
Dial-in InformationU.S. Dial-in
Number: (888) 645-5785International Dial-in Number:
(970) 300-1531Conference ID: 3674038
Replay InformationU.S. Dial-in
Number: (855) 859-2056Replay International Dial-in
Number: (404) 537-3406Conference ID: 3674038
The dial-in replay will be available for 14 days
following the call. An audio webcast will be available online in
the investor relations section of the company website at
www.lexpharma.com/investors, with a webcast replay accessible for
14 days after the call.
About Sotagliflozin
Discovered using Lexicon’s unique approach to
gene science, sotagliflozin is an investigational oral dual
inhibitor of two proteins responsible for glucose regulation known
as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2).
SGLT1 is responsible for glucose absorption in the gastrointestinal
tract, and SGLT2 is responsible for glucose reabsorption by the
kidney.
Lexicon entered into a collaboration and license
agreement with Sanofi in November 2015 under which Lexicon granted
Sanofi an exclusive, worldwide (excluding Japan), royalty-bearing
right and license to develop, manufacture and commercialize
sotagliflozin. Lexicon is responsible for all clinical development
activities relating to type 1 diabetes and has exercised an
exclusive option to co-promote and have a significant role, in
collaboration with Sanofi, in the commercialization of
sotagliflozin for the treatment of type 1 diabetes in the U.S.
Sanofi is responsible for all clinical development and
commercialization of sotagliflozin for the treatment of type 2
diabetes worldwide (excluding Japan) and is solely responsible for
the commercialization of sotagliflozin for the treatment of type 1
diabetes outside the U.S. (excluding Japan). A New Drug Application
(NDA) and a Marketing Authorization Application (MAA) for
sotagliflozin are currently under review at the U.S. Food and Drug
Administration and the European Medicines Agency (EMA),
respectively, and the product has not yet been approved for use in
the U.S. or in Europe.
About Lexicon
Pharmaceuticals
Lexicon is a fully integrated biopharmaceutical
company that is applying a unique approach to gene science based on
Nobel Prize-winning technology to discover and develop precise
medicines for patients with serious, chronic conditions. Through
its Genome5000™ program, Lexicon scientists have studied the role
and function of nearly 5,000 genes over the last 20 years and have
identified more than 100 protein targets with significant
therapeutic potential in a range of diseases. Through the precise
targeting of these proteins, Lexicon is pioneering the discovery
and development of innovative medicines to safely and effectively
treat disease. In addition to its first commercial product,
XERMELO® (telotristat ethyl), Lexicon has a
pipeline of promising drug candidates in clinical and pre-clinical
development in diabetes and metabolism and neuropathic pain. For
additional information please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking
statements,” including statements relating to Lexicon’s growth and
future operating results, discovery and development of products,
strategic alliances and intellectual property, as well as other
matters that are not historical facts or information. All
forward-looking statements are based on management’s current
assumptions and expectations and involve risks, uncertainties and
other important factors, specifically including those relating to
Lexicon’s ability to meet its capital requirements, successfully
conduct preclinical and clinical development of its drug
candidates, obtain necessary regulatory approvals, achieve its
operational objectives, obtain patent protection for its
discoveries and establish strategic alliances, as well as
additional factors relating to manufacturing, intellectual property
rights, and the therapeutic or commercial value of its drug
candidates, that may cause Lexicon’s actual results to be
materially different from any future results expressed or implied
by such forward-looking statements. Information identifying
such important factors is contained under “Risk Factors” in
Lexicon’s annual report on Form 10-K for the year ended December
31, 2017, as filed with the Securities and Exchange
Commission. Lexicon undertakes no obligation to update or
revise any such forward-looking statements, whether as a result of
new information, future events or otherwise.
For Investor Inquiries:
Kimberly Lee, D.O.Head of Investor Relations and
Corporate StrategyLexicon Pharmaceuticals(281)
863-3383klee@lexpharma.com
For Media Inquiries:
Chas SchultzExecutive Director, Corporate
Communications and Patient AdvocacyLexicon Pharmaceuticals(281)
863-3421cschultz@lexpharma.com
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024